serolog
assay
frequent
use
familiar
test
laboratori
diagnosi
lyme
diseas
present
unit
state
test
current
clear
diagnost
use
us
feder
drug
administr
fda
serolog
assay
current
guidelin
serolog
test
adopt
challeng
dearborn
confer
particip
develop
test
interpret
guidelin
would
standard
serolog
test
diagnost
purpos
guidelin
gear
assess
exposur
b
burgdorferi
patient
antibodi
respons
infect
rather
direct
detect
nucleic
acid
protein
microb
limit
serolog
test
advanc
recent
report
detail
lag
period
infect
b
burgdorferi
week
may
need
infect
bcell
product
pathogenspecif
antibodi
suffici
quantiti
detect
current
serolog
assay
also
immunoglobulin
reactiv
fraught
issu
affect
util
cultur
pathogen
microbi
nucleic
acid
protein
may
detect
skin
biopsi
erythema
migran
em
develop
posit
serolog
howev
cultur
impract
routin
clinic
use
requir
special
media
b
burgdorferi
grow
slowli
requir
week
come
detect
although
improv
serolog
assay
forese
current
assay
util
antigen
target
identifi
thorough
understand
express
antigen
epitop
key
earli
antigen
target
miss
assay
contribut
insensit
serolog
earli
infect
also
crossreact
epitop
found
virtual
antigen
use
current
approv
seroassay
earli
manifest
may
rang
asymptomat
without
known
tick
bite
impract
test
asymptomat
tick
bite
nonspecif
symptom
specif
one
em
serolog
test
detect
exposur
pathogen
indirectli
via
quantif
specif
antibodi
blood
independ
whether
infect
past
current
contrast
direct
test
design
detect
etiolog
agent
compon
test
could
advantag
diagnosi
earli
lyme
diseas
absenc
em
sign
symptom
lyme
diseas
nonspecif
clinic
diagnost
patient
virallik
symptom
earli
lyme
diseas
without
em
serolog
test
may
yet
posit
direct
test
could
provid
definit
indic
activ
b
burgdorferi
infect
later
diseas
directdetect
method
may
help
confirm
presenc
pathogen
cultur
b
burgdorferi
requir
special
media
organ
grow
slowli
take
week
seen
rel
low
sensit
cultur
continu
research
tool
cultureconfirm
techniqu
beyond
capabl
clinic
laboratori
antigencaptur
assay
provid
one
mean
direct
detect
bacteria
often
shed
secret
antigen
detect
bodi
fluid
exampl
legionellosi
cryptococcosi
aspergillosi
dimorph
fungal
infect
diagnos
use
antigen
test
appli
urin
blood
bronchoalveolar
lavag
cerebrospin
fluid
direct
test
lyme
diseas
need
sensit
specif
antigencaptur
assay
elus
even
antigen
known
present
sampl
past
attempt
develop
antigencaptur
assay
poor
specif
low
sensit
uncertainti
choic
captur
antigen
target
specif
sensit
antigendetect
assay
larg
function
choic
captur
report
antigen
target
well
affin
antibodi
use
captur
detect
depend
durat
infect
b
burgdorferi
antigen
repertoir
chang
addit
high
sequenc
variabl
b
burgdorferi
strain
identif
conserv
antigen
epitop
span
strain
time
challeng
across
genospeci
one
select
appropri
target
antigen
genospeci
even
ospc
known
variabl
least
wellconserv
epitop
target
found
across
variou
serotyp
earlier
attempt
creat
antigencaptur
assay
may
hinder
lack
data
optim
select
target
antibodi
advanc
proteom
specimen
process
mass
spectrometri
identif
pathogenspecif
antigen
possibl
repres
path
forward
although
larg
commerci
laboratori
use
mass
spectrometri
diagnost
purpos
lyme
diseas
methodolog
use
identifi
valid
specif
complex
simpler
assay
develop
use
routin
laboratori
set
perhap
even
closer
point
care
addit
emerg
antigen
concentr
enrich
method
potenti
address
anoth
like
burgdorferispecif
antigen
probabl
low
abund
bodi
fluid
throughout
b
burgdorferi
infect
circul
organ
organ
burden
affect
organ
low
concentr
method
categor
follow
remov
solut
water
electrophoret
chromatograph
separ
affin
captur
along
target
enrich
method
may
requir
exclus
mask
protein
common
abund
protein
frequent
prepar
step
prior
mass
spectrometri
detect
protein
new
develop
stabil
protein
sampl
prior
analysi
may
suitabl
sever
assay
infecti
agent
difficult
visual
cultiv
nucleic
acid
amplif
test
naat
identifi
specif
pathogen
dna
mani
pathogen
easili
detect
use
naat
especi
high
enhanc
enrich
method
present
mani
polymeras
chain
reaction
pcr
assay
gear
analyz
small
volum
blood
plasma
sampl
type
lyme
diseas
outsid
em
skin
infecti
agent
resid
low
number
tissu
bodi
fluid
standard
pcr
method
appli
b
burgdorferi
detect
suffer
poor
sensit
especi
blood
cerebrospin
fluid
illustr
strategi
increas
pcr
sensit
without
diminish
specif
start
larger
specimen
volum
andor
use
target
enrich
method
appear
possibl
detect
b
burgdorferi
blood
higher
sensit
earli
lyme
diseas
addit
varieti
pcrbase
assay
develop
use
unconvent
signal
detect
amplif
method
potenti
achiev
limit
detect
lod
substanti
lower
standard
pcr
method
today
advanc
directdetect
diagnost
tool
avail
time
dearborn
recommend
ensu
year
pcr
highthroughput
sequenc
matur
routin
use
detect
mani
new
pathogen
techniqu
appli
success
lyme
diseas
diagnost
improv
lyme
diseas
assay
perform
equal
better
exist
serolog
enzym
immunoassay
follow
western
blot
advantag
naat
measur
presenc
microb
therefor
activ
infect
especi
found
circul
fluid
instead
host
antibodi
respons
b
burgdorferi
pcr
strategi
perform
well
blood
test
caus
agent
sepsi
ebola
infect
mani
genom
copi
detect
methodolog
gear
small
volum
blood
plasma
contrast
lyme
diseas
low
microb
number
major
clinic
sampl
enhanc
enrich
method
detect
b
burgdorferi
blood
increasingli
possibl
multipl
displac
amplif
similar
strategi
dna
exponenti
amplifi
isotherm
amplif
increas
yield
b
burgdorferi
least
time
normal
make
pcr
detect
assay
far
sensit
studi
sensit
pcrbase
assay
increas
order
combin
consecut
method
similar
approach
use
blood
cultur
sepsi
multipl
larg
volum
blood
taken
first
step
start
larger
volum
whole
blood
ml
ml
plasma
serum
often
request
clinic
laboratori
second
step
increas
rel
content
b
burgdorferi
compar
human
microbi
dna
use
target
isotherm
amplif
vitro
experi
result
increas
target
dna
set
clinic
em
sampl
number
case
detect
greater
without
step
third
step
increas
sensit
specif
use
multipl
primer
note
appear
skinrestrict
genotyp
may
reason
neg
result
blood
also
consid
enrich
concentr
pathogen
increas
target
concentr
nucleic
acid
extract
follow
pcr
analysi
addit
hope
point
futur
acut
naat
develop
acut
lyme
diseas
studi
document
number
organ
dna
blood
may
higher
appreci
highthroughput
sequenc
ht
also
known
nextgener
sequenc
ng
breakthrough
method
identifi
character
nucleic
acid
divers
microb
howev
b
burgdorferi
particularli
challeng
part
present
low
abund
circul
fluid
unusu
genom
approxim
mb
bbl
genom
atrich
approxim
nearli
half
consist
linear
circular
plasmid
borrelia
burgdorferi
isol
averag
plasmid
type
strain
thu
borrelia
genom
among
complex
challeng
bacteri
genom
sequenc
analyz
difficulttosequ
plasmid
carri
antigenencod
gene
often
requir
propag
bacteria
tick
andor
mammal
recent
develop
longread
sequenc
technolog
eg
pacif
bioscienc
combin
use
ht
technolog
rel
low
sequenc
error
rate
eg
illumina
nova
miseq
platform
allow
resolut
repeat
sequenc
hallmark
borrelia
genom
sequenc
challeng
commonli
found
critic
import
borrelia
plasmid
addit
use
character
b
burgdorferi
genom
ng
could
potenti
use
directdetect
method
clinic
diagnost
target
deep
sequenc
eg
enrich
desir
genom
region
prior
sequenc
via
either
hybrid
pcr
amplif
techniqu
prove
achiev
adequ
sensit
emerg
approach
sequenc
cellfre
dna
plasma
show
promis
sequenc
also
allow
much
better
resolut
speci
strain
either
multilocu
sequenc
sequenc
strategi
wholegenom
sequenc
approach
rapidli
decreas
cost
perform
sequenc
may
make
viabl
highthroughput
multipl
sampl
character
time
method
detect
clinic
laboratori
appropri
sensit
establish
challeng
remain
howev
includ
incomplet
knowledg
full
breadth
borrelia
genom
divers
gene
might
share
isol
also
call
core
genom
might
uniqu
specif
speci
also
call
accessori
genom
without
critic
knowledg
would
challeng
determin
precis
gene
antigen
target
select
diagnost
test
pcr
ht
technolog
valu
authent
sampl
actual
infect
organ
proof
infect
valuabl
assay
develop
includ
improv
serolog
research
assum
yet
proven
preferenti
window
nucleic
acid
detect
blood
earliest
point
infect
well
serolog
assay
tend
posit
may
untreat
patient
borrelia
dna
may
detect
deep
sequenc
hybrid
target
enrich
background
subtract
import
realiz
certain
molecular
techniqu
may
expens
routin
clinic
use
least
current
may
requir
curat
genom
proteom
databas
higher
qualiti
current
publicli
avail
limit
genom
test
particularli
larg
scale
requir
attent
risk
exogen
contamin
degrad
nucleic
acid
transport
laboratori
complex
techniqu
make
test
hundr
sampl
day
difficult
costbenefit
factor
howev
use
current
avail
tool
research
abl
help
defin
paramet
optim
natur
requir
volum
sampl
degre
target
amplif
sequenc
captur
host
background
suppress
need
lod
must
achiev
knowledg
could
help
drive
develop
econom
viabl
assay
could
eventu
go
regulatori
review
process
routin
clinic
use
requir
concentr
research
follow
product
develop
regulatori
approv
robust
afford
reliabl
directdetect
assay
avail
routin
diagnost
use
new
improv
assay
one
contempl
fda
clearanc
advis
initi
earli
direct
commun
fda
includ
particip
qsub
program
develop
may
receiv
assayspecif
feedback
new
technic
advanc
knowledg
demonstr
direct
test
earli
activ
infect
readi
practic
assess
lyme
diseas
futur
test
also
like
test
guidelin
lyme
diseas
adopt
intend
make
best
use
avail
assay
antibodi
test
provid
indirect
evid
infect
although
guidelin
improv
standard
serolog
test
aspect
amen
improv
light
new
data
technolog
continu
relianc
serolog
test
earli
lyme
diseas
suboptim
given
common
week
seroneg
window
current
method
need
biomark
activ
infect
goal
activeinfect
diagnost
test
technic
achiev
evalu
practic
perform
clinic
set
tabl
direct
nucleic
acid
protein
detect
would
complement
improv
indirect
serolog
test
comprehens
diagnosi
lyme
diseas
